A small molecule screen of 1124 compounds identified multiple β2-adrenoreceptor agonists that lower SNCA mRNA abundance (38), resulting in an epidemiologic study of nearly 2 million adults that indicated that the use of β2-adrenoreceptor agonists could significantly reduce the risk of PD (39). The gene discussed is SNCA; the disease is Parkinson disease.